Validity and reliability of the Indonesian version of the 9-item Inflammatory Bowel Disease Questionnaire (IBDQ-9)

  • Dekta Filantropi Esa Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Hamzah Shatri Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Cleopas Martin Rumende Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Adityo Susilo Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Hasan Maulahela Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Achmad Fauzi Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Marcellus Simadibrata Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
DOI: https://doi.org/10.13181/mji.oa.236848
Keywords: inflammatory bowel disease, quality of life
Abstract viewed: 153 times
PDF downloaded: 106 times
HTML downloaded: 31 times
EPUB downloaded: 39 times
Supplementary File downloaded: 34 times

Abstract

BACKGROUND Decreasing the quality of life (QoL) of patients with inflammatory bowel disease (IBD) will increase morbidity and mortality. A valid and reliable instrument is needed to assess the QoL of patients with IBD. This study aimed to analyze the validity and reliability of the Indonesian version of the 9-item Inflammatory Bowel Disease Questionnaire (IBDQ-9).

METHODS This cross-sectional study was conducted using the Indonesian version of the IBDQ-9 in adult patients with IBD at the Gastroenterology Outpatient Clinic, Cipto Mangunkusumo Hospital, Jakarta, in November 2022. Patients aged 18 to 59 years who had experienced IBD for at least 2 weeks and provided informed consents were included. The total score of the IBDQ-9 Indonesian version was compared with the 36-item Short-Form Health Survey (SF-36) using the Spearman's correlation test. Reliability tests were examined using Cronbach’s alpha and the intraclass correlation coefficient (ICC).

RESULTS A total of 124 participants were included in this study. The Spearman's test showed a high and significant result for the IBDQ-9 Indonesian version and the SF-36 (r = 0.769 and p<0.001). Cronbach’s alpha and ICC coefficient were equal to 0.883.

CONCLUSIONS This study provided evidence of the good validity and reliability of the IBDQ-9 Indonesian version for assessing the QoL of patients with IBD in Indonesia.

References

  1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-78. https://doi.org/10.1056/NEJMra0804647

  2. Vegh Z, Kurti Z, Lakatos PL. Epidemiology of inflammatory bowel diseases from west to east. J Dig Dis. 2017;18(2):92-8. https://doi.org/10.1111/1751-2980.12449

  3. Makmun D, Renaldi K, Maulahela H, Utari AP, Pribadi RR, Muzellina VN, et al. [National consensus on management of inflammatory bowel disease (IBD) in Indonesia (revised 2019)]. Makmun D, Fauzi A, Maulahela A, Pribadi RR, editors. Jakarta: Interna Publishing; 2019. p. 1-52. Indonesian.

  4. Huppertz-Hauss G, Høivik ML, Langholz E, Odes S, Småstuen M, Stockbrugger R, et al. Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015;21(2):337-44. https://doi.org/10.1097/MIB.0000000000000272

  5. Alcalá MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(4):383-91. https://doi.org/10.1097/00054725-200407000-00009

  6. Gholamrezaei A, Haghdani S, Shemshaki H, Tavakoli H, Emami MH. Linguistic validation of the inflammatory bowel disease questionnaire-short form (IBDQ-9) in Iranian population. J Isfahan Med Sch. 2011;28(123):1850-9.

  7. Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL; ECCO-EpiCom. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8(11):1351-61. https://doi.org/10.1016/j.crohns.2014.05.006

  8. Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17(7):1045-7. https://doi.org/10.1111/ggi.13118

  9. United Nations Department of Economic and Social Affairs, Population Division. World population prospects 2022: summary of results. United Nations: New York; 2022. p. 1-9. UN DESA/POP/TR/NO.3.

  10. Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107-15. https://doi.org/10.1038/s41395-018-0233-2

  11. Ng SC, Zeng Z, Niewiadomski O, Tang W, Bell S, Kamm MA, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology. 2016;150(1):86-95.e3; quiz e13-4. https://doi.org/10.1053/j.gastro.2015.11.019

  12. Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel. Intest Res. 2021;19(1):45-52. https://doi.org/10.5217/ir.2019.00135

  13. M'Koma AE. The multifactorial Etiopathogeneses interplay of inflammatory bowel disease: an overview. Gastrointest Disord (Basel). 2019;1(1):75-105. https://doi.org/10.3390/gidisord1010007

  14. Villoria A, García V, Dosal A, Moreno L, Montserrat A, Figuerola A, et al. Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. PLoS One. 2017;12(7):e0181435. https://doi.org/10.1371/journal.pone.0181435

  15. Magharei M, Jaafari S, Mansouri P, Safarpour A, Taghavi SA. Effects of self-management education on self-efficacy and quality of life in patients with ulcerative colitis: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2019;7(1):32-42.

  16. Neubauer K, Arlukiewicz A, Paradowski L. Quality of life in inflammatory bowel disease. Adv Clin Exp Med. 2009;18(1):79-83.

  17. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. https://doi.org/10.1038/s41572-020-0205-x

  18. Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, et al. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res. 2018;27(2):273-90. https://doi.org/10.1007/s11136-017-1690-6

  19. Chen XL, Zhong LH, Wen Y, Liu TW, Li XY, Hou ZK, et al. Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties. Health Qual Life Outcomes. 2017;15(1):177. https://doi.org/10.1186/s12955-017-0753-2

  20. Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm Bowel Dis. 2018;24(4):742-51. https://doi.org/10.1093/ibd/izx100

  21. López-Vico M, Sánchez-Capilla AD, Redondo-Cerezo E. Quality of life in cohabitants of patients suffering inflammatory bowel disease: a cross-sectional study. Int J Environ Res Public Health. 2021;19(1):115. https://doi.org/10.3390/ijerph19010115

Published
2023-12-22
How to Cite
1.
Esa DF, Shatri H, Rumende CM, Susilo A, Maulahela H, Fauzi A, Simadibrata M. Validity and reliability of the Indonesian version of the 9-item Inflammatory Bowel Disease Questionnaire (IBDQ-9). Med J Indones [Internet]. 2023Dec.22 [cited 2024May1];32(3):168-72. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/6848
Issue
Vol. 32 No. 3 (2023): September
Section
Clinical Research

Copyright (c) 2023 Dekta Filantropi Esa, Hamzah Shatri, Cleopas Martin Rumende, Adityo Susilo, Hasan Maulahela, Achmad Fauzi, Marcellus Simadibrata

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

Most read articles by the same author(s)